Acceleron Pharma

^{Priced, Nasdaq: XLRN.XX}

Clinical-stage biotech developing protein therapeutics for cancer and rare diseases.

Industry: Health Care

First Day Return: +33.3%

XLRN.XX

Clinical-stage biotech developing protein therapeutics for cancer and rare diseases.

IPO News for Acceleron Pharma

Muscular dystrophy biotech aTyr Pharma sets terms for $75 million IPO 04/27/15
Muscular dystrophy biotech aTyr Pharma files for a $86 million IPO 04/06/15
US IPO Recap: Blazing debuts for software trio FireEye, Rocket Fuel and Benefitfocus 09/23/13

IPO Data
IPO Date	09/18/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$84
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.acceleronpharma.com
Headquarters	Cambridge, MA, United States
Founded	2003
Employees at IPO	78

IPO News for Acceleron Pharma

Acceleron Pharma (XLRN.XX) Performance